MANCHESTER diagnostics specialist DxS spent nearly £250,000 exploring a stock market flotation before it was sold to the Dutch group Qiagen.

New accounts for the 12 months to June, 2009, show the business incurred an exceptional cost of £249,632 associated with an aborted initial public offering.

Until September a syndicate of venture capital investors, led by NVM Private Equity, controlled the business and were seeking an exit either through a floation or a sale.

They settled on the latter option,......for the full story register now for free or login below...